Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV)

The National Institute for Health and Care Excellence has refused to authorize AbbVie Inc (NYSE:ABBV)‘s Venclyxto on NHS. Besides the price, the National Institute for Health and Care Excellence also cited doubts regarding the evidence presented by AbbVie that the drug was effective.

The appraisal committee of NICE said that the results of the trials were possibly biased because of the single-arm design that was applied in conducting the trials. Additionally, only a few patients were involved in the trials.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

“The patients in the comparator trial did not reflect those for whom venetoclax may be option,” said the committee.

Too High A Price

With regards to the price of the drug, the National Institute for Health and Care Excellence also expressed concerns about the price. In normal circumstances, the only drugs accepted by the National Institute for Health and Care Excellence are those that can offer a QALY (quality-adjusted life year) at a maximum cost of not more than £30,000. The price of Venclyxto was higher than this.

One wonders why worries about whether prices are too high or not is not determined by customers rather than bureaucrats.

This is a blow to AbbVie Inc (NYSE:ABBV) since it was looking to benefit from its BCL-2 inhibitor being the first in the market. At the moment, the drug is being used by a small number of patients who suffer from conditions that are harder to treat. The rejection by NICE is thus preventing AbbVie from reaching a wider pool of patients.

Better Prospects Going Forward

In the earnings call during the release of the results for the fourth quarter of 2016, executives from AbbVie Inc (NYSE:ABBV) said they expected the lymphocytic leukemia drug to bring in revenues of about $125 million in 2017. The market, which currently has Imbruvica as the leader, is worth approximately $300 million. In the next ten years, however, analysts are of the view that with more of its products getting approval from the U.S. Food and Drug Administration, revenues will rise to reach a level of between $1.5 billion and $2 billion in the next ten years.

In Wednesday’s trading session, shares of AbbVie Inc (NYSE:ABBV) edged up by 1.36 percent to close the day at $61.65.

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.